Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 39
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Ann Otolaryngol Chir Cervicofac ; 122(5): 246-55, 2005 Nov.
Artículo en Francés | MEDLINE | ID: mdl-16439935

RESUMEN

OBJECTIVES: The aim of this study was to compare the efficacy and tolerance of Dérinox (D) to Rhinofluimucil (R) and placebo (P) in the treatment of common cold, using an objective measure of nasal obstruction, the Peak Nasal Inspiratory Flow (PNIF--Clement Clarke International, Harlow, Angleterre). PATIENTS AND METHODS: This randomized, double-blind, double-dummy, parallel group study enrolled 354 patients (34 P, 165 D et 155 R) included by 85 general practitioners. The treatment duration was 5 days at usual recommended dosage regimens. PNIF measures were done before drug administration (T0) as well as 15 min and 3 h after each intake. Moreover, nasal obstruction, rhinorrhea and global discomfort were subjectively assessed. RESULTS: The efficacy of D was superior to that of P and R when comparing PNIF from T0 to T3 h after the first intake. At T15 min, rhinorrhea was significantly improved with both active treatments and global discomfort was significantly improved with D only. Treatment tolerance was satisfactory and comparable between the 3 groups. CONCLUSION: Efficacy of Dérinox(R) was superior to that of P and R for the improvement of the nasal obstruction (PNIF) between T0 and T3h (main criteria) after the first intake in patients suffering from common cold.


Asunto(s)
Acetilcisteína/uso terapéutico , Aminas/uso terapéutico , Nafazolina/uso terapéutico , Descongestionantes Nasales/uso terapéutico , Obstrucción Nasal/tratamiento farmacológico , Prednisolona/uso terapéutico , Rinitis/tratamiento farmacológico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Método Doble Ciego , Combinación de Medicamentos , Femenino , Humanos , Inhalación , Masculino , Persona de Mediana Edad , Obstrucción Nasal/diagnóstico , Obstrucción Nasal/etiología , Pruebas de Función Respiratoria , Rinitis/complicaciones , Rinitis/diagnóstico , Rinitis/virología
2.
Psychopharmacology (Berl) ; 157(3): 228-35, 2001 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-11605077

RESUMEN

RATIONALE: Neuroleptic or antipsychotic drugs are the mainstay of treating acute and chronic psychosis. However, their efficacy is offset by a wide array of side effects, especially extrapyramidal syndromes (EPS). In an attempt to develop novel antipsychotic agents, several animal models have been developed to characterize the profile of new chemical entities. OBJECTIVE: To evaluate the behavioral characteristics of JL 13, a potentially unique antipsychotic agent, three separate studies across a wide dose range in Cebus monkeys were conducted and compared with two studies of oral and parenteral haloperidol. METHODS: Twelve Cebus monkeys were tested with single i.m. doses of JL 13 (0.1-2.5 mg/kg), single p.o. doses (1.0-50.0 mg/kg), and 35 days of continuous p.o. (up to 25 mg/kg) treatments and were blindly evaluated. The same twelve monkeys were also tested with haloperidol i.m. (0.01-0.25 mg/kg) and nine of the monkeys also received haloperidol p.o. (0.1-5.0 mg/kg). Behaviors scored included sedation/arousal, locomotor activity, EPS of parkinsonism and dystonia, as well as reactivity. RESULTS: JL 13 produced mild to moderate and dose-related increased sedation and decreased locomotor activity. Minimal decreases in eye blinking rates were also noted as a consequence of sedation. Mild dystonia and parkinsonian symptoms of slow movement developed at the highest dose tested of 50 mg/kg p.o. in only 6 of 12 monkeys. This is 50 times higher than oral doses of haloperidol that would be needed to produce similar EPS effects. Dose-related EPS of dystonia and bradykinesia occurred in relation to decreased locomotor activity and reactivity to stimuli with haloperidol i.m. and p.o., which are features characteristically seen with traditional neuroleptics. CONCLUSIONS: The behavioral effects of JL 13 in non-human primates suggest this compound is well tolerated and may have a favorable antipsychotic benefit/risk ratio in the clinic, especially if antipsychotic efficacy occurs at doses well below those that can cause EPS.


Asunto(s)
Antipsicóticos/farmacología , Conducta Animal/efectos de los fármacos , Oxazepinas/farmacología , Piperazinas/farmacología , Piridinas/farmacología , Administración Oral , Animales , Parpadeo/efectos de los fármacos , Cebus , Femenino , Haloperidol/farmacología , Inyecciones Intramusculares , Masculino , Factores de Tiempo
3.
J Pharmacol Exp Ther ; 298(1): 386-91, 2001 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-11408566

RESUMEN

JL13 [5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5] benzoxazepine fumarate] is a substance with a close structural resemblance to clozapine. However, it is less sensitive to oxidation and may therefore have less hematological side effects. In the present study, JL13 was compared with clozapine and haloperidol in several animal models for schizophrenia. The paw test represents a screening model for antipsychotic drugs that can discriminate between drugs with extrapyramidal side effects and drugs without. Haloperidol increased both forelimb retraction time and hindlimb retraction time (HRT), whereas both clozapine and JL13 increased only HRT. In the prepulse inhibition paradigm, all three drugs reversed the apomorphine- and the amphetamine-induced disruption of prepulse inhibition. However, whereas haloperidol was equally effective against both dopaminergic drugs, JL13 and clozapine were more effective against amphetamine. Finally, only JL13 was able to increase prepulse inhibition in normal rats, whereas only clozapine reduced basal startle amplitude. Taken together, these data suggest that JL13 may be an effective antipsychotic drug, with a profile similar to clozapine.


Asunto(s)
Antipsicóticos/farmacología , Clozapina/farmacología , Modelos Animales de Enfermedad , Locomoción/efectos de los fármacos , Reflejo de Sobresalto/efectos de los fármacos , Esquizofrenia , Anfetamina , Animales , Antipsicóticos/uso terapéutico , Benzodiazepinonas/química , Estimulantes del Sistema Nervioso Central , Clozapina/análogos & derivados , Clozapina/uso terapéutico , Evaluación Preclínica de Medicamentos , Haloperidol/farmacología , Haloperidol/uso terapéutico , Locomoción/fisiología , Masculino , Piridinas/química , Ratas , Ratas Wistar , Reflejo de Sobresalto/fisiología , Esquizofrenia/tratamiento farmacológico
4.
J Med Chem ; 44(5): 769-76, 2001 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-11262087

RESUMEN

The chemical modification of clozapine (1) has permitted the finding of new analogues, e.g., olanzapine (2), quetiapine (3), 5-(4-methylpiperazin-1-yl)-8-chloropyrido[2,3-b][1,5]benzoxazepine fumarate (9), with a clinical or psychopharmacological profile similar to that of clozapine. However, when developing new derivatives, the designers are discouraged by the development of clozapine-induced agranulocytosis. Different researchers have raised the role played by the oxidizability of the molecule in such a deleterious effect. In the present paper, we examined the oxidation profile (direct scavenging abilities, efficacy in inhibiting lipid peroxidation, and electrooxidation potential) of newly developed methoxy and trifluoromethylsulfonyloxy analogues related to clozapine, some of them being described as putative antipsychotic. The oxazepine derivative 7, unlike the other diazepine derivatives (6, 10--12), was not readily oxidized. Using a statistical predictive model for hematotoxicity previously described, 7 was found in the cluster of potentially nontoxic compounds while diazepine derivatives 6 and 10-12 were classified as potentially toxic compounds. Among these original compounds, 7, which presents a preclinical clozapine-like profile and a low sensitivity to oxidation, could be a promising antipsychotic candidate with low side effects. Considering the tricyclic derivatives examined so far, some elements of structure-oxidation relationship (SOR) might be pointed out. Regarding the nature of the tricyclic ring substituent, from the most to the least sensitive to oxidation, the sequence was as follows: HO > Cl > CH(3)O > CF(3)SO(2)O. The nature of the tricyclic ring influenced also the sensitivity to oxidation; the diazepine moiety appeared to be the most reactive ring compared to oxa- and thiazepine congeners. These parameters could be advantageously integrated in the early design of new safer clozapine-like analogues.


Asunto(s)
Antipsicóticos/síntesis química , Clozapina/análogos & derivados , Clozapina/síntesis química , Antioxidantes/síntesis química , Antioxidantes/química , Antioxidantes/toxicidad , Antipsicóticos/química , Antipsicóticos/toxicidad , Clozapina/química , Clozapina/toxicidad , Electricidad , Peroxidasa de Rábano Silvestre , Peroxidación de Lípido/efectos de los fármacos , Análisis Multivariante , Oxidación-Reducción , Relación Estructura-Actividad
5.
Psychopharmacology (Berl) ; 151(4): 328-34, 2000 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-11026739

RESUMEN

The inclusion of a drug into cyclodextrin generally results in the modification of its physical and chemical properties and sometimes can increase its oral bioavailability. The aim of this study was to compare the effects of the fluoxetine HCl/gamma-cyclodextrin complex to that of traditional fluoxetine HCl. In the forced swimming test in mice, fluoxetine HCl/gamma-cyclodextrin was more effective than fluoxetine HCl, the ED30s being, respectively, 9.5 and 16.9 mg/kg PO. Both compounds (10 mg/kg PO) were able to reduce the firing rate of dorsal raphe neurons in the rat. However, between-groups comparisons showed no significant differences between fluoxetine HCl treated animals and the vehicle group, while fluoxetine HCl/gamma-cyclodextrin appeared significantly more effective than vehicle from minute 25 of the measurement period. In healthy volunteers, the relative oral bioavailability, calculated as the ratio AUC 0-infinity fluoxetine HCl/gamma-cyclodextrin on AUC 0-infinity fluoxetine HCl (20 mg PO), was equal to 249.9%. The three experiments taken together suggest that the complexation of fluoxetine HCl into gamma-cyclodextrin increases its pharmacological efficacy in animals, this effect being related to an enhancement of its oral bioavailability as demonstrated in human healthy subjects.


Asunto(s)
Ciclodextrinas/administración & dosificación , Fluoxetina/administración & dosificación , Inhibidores Selectivos de la Recaptación de Serotonina/administración & dosificación , gamma-Ciclodextrinas , Adolescente , Adulto , Animales , Disponibilidad Biológica , Fluoxetina/análogos & derivados , Fluoxetina/farmacocinética , Fluoxetina/farmacología , Humanos , Masculino , Ratones , Persona de Mediana Edad , Estudios Prospectivos , Núcleos del Rafe/efectos de los fármacos , Núcleos del Rafe/fisiología , Ratas , Ratas Wistar , Natación
6.
Arch Pharm (Weinheim) ; 333(2-3): 63-7, 2000 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-10783520

RESUMEN

JL 13 (5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b]- [1,5]benzoxazepine fumarate) and JL 3 (10-(4-methylpiperazin-1- yl)pyrido[4,3-b][1,4]benzothiazepine), two pyridobenzazepine derivatives structurally related to clozapine, were selected for further development. Due to their structural similarity to clozapine, they are haunted by the spectre of clozapine-induced agranulocytosis. In a previous study, JL 13 was shown to be less sensitive to oxidation than clozapine. In the present paper, using an in vitro procedure, we report the effect of hypochlorous acid (HOCl), a major in vivo oxidant, on both drugs. It appears that the oxidations of JL 3 and JL 13, unlike clozapine, are very slow and little secondary product is formed. Moreover, in contrast to clozapine, the products that were formed are not reactive and thus do not react with glutathione or N-acetylcysteine. Thus, if, as postulated for clozapine, drug-induced agranulocytosis is due to a reactive metabolite formed by neutrophils or their precursors, JL 3 and JL 13 would not be expected to cause the same adverse reaction.


Asunto(s)
Clozapina/análogos & derivados , Ácido Hipocloroso/farmacología , Tiazepinas/metabolismo , Antipsicóticos/efectos adversos , Antipsicóticos/metabolismo , Clozapina/efectos adversos , Clozapina/metabolismo , Humanos , Ácido Hipocloroso/metabolismo , Técnicas In Vitro , Neutrófilos/metabolismo , Oxidantes/metabolismo , Oxidantes/farmacología , Oxidación-Reducción
7.
Arch Biochem Biophys ; 370(1): 126-37, 1999 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-10496986

RESUMEN

Some antipsychotic agents have been found to produce agranulocytosis and aplastic anemia. The oxidation phenomena and/or the formation of free radicals has been suggested to be causally related to various hematological disorders, e.g., agranulocytosis. Using five experimental conditions, we tested the oxidative potential of compounds with and without a history of hematological side effects, e.g., agranulocytosis and aplastic anemia. A statistical analysis was undertaken for each experimental condition and a multivariate analysis combining all results was performed. Two peroxidase-induced free radical models did not successfully discriminate between drugs with and without a history of causing hematologic problems (<70%). The lipid peroxidation system provided even less satisfactory discrimination, with only 56.25% correct classification. However, an 87.5% correct classification was obtained when using the oxidation potentials of these drugs determined at pH 4.7 and at pH 7.4. A multivariate analysis taking into account the five variables provided 87.5% success in classification. The two clusters were better discriminated in terms of a "distance coefficient." In a second analysis, the putative antipsychotic pyridobenzodiazepine analogues (JL5, JL8, JL18, and JL25) were classified in the cluster of toxic compounds, while the oxa- and thiazepine analogues (JL2, JL3, and JL13) were classified as nontoxic compounds. On the other hand, a few metabolites of clozapine and fluperlapine were classified in the toxic compound group. The procedure described herein is, to our knowledge, the first which classifies molecules of different structures as well as different pharmacological profiles according to their hematotoxic potential. Such a procedure could be used to predict drug-induced hematological side effects.


Asunto(s)
Antipsicóticos/química , Antipsicóticos/toxicidad , Benzazepinas/química , Enfermedades Hematológicas/inducido químicamente , Peroxidasa de Rábano Silvestre/metabolismo , Pirimidinonas/química , Agranulocitosis/inducido químicamente , Anemia Aplásica/inducido químicamente , Antipsicóticos/farmacocinética , Benzazepinas/farmacocinética , Benzazepinas/toxicidad , Espectroscopía de Resonancia por Spin del Electrón , Humanos , Oxidación-Reducción , Pirimidinonas/farmacocinética , Pirimidinonas/toxicidad , Relación Estructura-Actividad
8.
Eur J Pharmacol ; 386(2-3): 211-6, 1999 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-10618472

RESUMEN

Using in vitro electrophysiological procedures, we confirm the inhibitory effect of 10-(4-methylpiperazin-1-yl)pyrido[4,3-b][1, 4]benzothiazepine (JL 3), on dorsal raphe serotonergic (IC(50)=14 microM) and noradrenergic neurons (IC(50)=4.5 microM). The effect on dorsal raphe neurons was reduced by N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinyl- cyclohexanecarboxamide (WAY-100635), suggesting the importance of 5-HT(1A) receptor stimulation. Yohimbine, and ritanserin, to a lesser extent, blocked the inhibitory effect of JL 3 on locus coeruleus neurons indicating that alpha(2)-adrenoceptors and 5-HT(2A) receptors may be implicated in the effects. Because of its negligible alpha(2)-adrenoceptor affinity, the effect of JL 3 on locus coeruleus neurons, would have to be indirect. JL 3 may interfere with the norepinephrine transporter site (IC(50)=0.34 microM). JL 3 tended to reinforce the hypertensive effect of norepinephrine, while it strongly inhibited the hypertensive effect of tyramine, further indicating an interaction at the norepinephrine transporter site level.


Asunto(s)
Antidepresivos/farmacología , Neuronas/efectos de los fármacos , Receptores Adrenérgicos/metabolismo , Receptores de Serotonina/metabolismo , Tiazepinas/farmacología , Inhibidores de Captación Adrenérgica/farmacología , Animales , Interacciones Farmacológicas , Técnicas In Vitro , Locus Coeruleus/efectos de los fármacos , Locus Coeruleus/metabolismo , Masculino , Neuronas/metabolismo , Norepinefrina/farmacología , Núcleos del Rafe/efectos de los fármacos , Núcleos del Rafe/metabolismo , Ratas , Ratas Wistar , Tiramina/farmacología
9.
Curr Med Chem ; 5(2): 77-100, 1998 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-9481035

RESUMEN

Classically, the D2 receptors formed the core of the dopamine hypothesis for schizophrenia. Recently, the dopamine D4 receptors have received particular attention in this context. This is due to the atypical antipsychotic, clozapine, which is effective in treating refractory schizophrenics without the side-effect profile of typical neuroleptics, and displays a ten-fold higher affinity for D4 compared to D2 or D3 receptors. Following various reports presenting the interest of D4 receptors in treating schizophrenia, multiple chemical developments were made. During the last five years, various structures were described with a high selectivity for D4 receptor subtype. Currently, although the first clinical report was very disappointing, the observation which support the idea that D4 might serve as a target for clozapine have significantly modified and extended the understanding of mechanism underlying atypical antipsychotic treatment of schizophrenia.


Asunto(s)
Antipsicóticos/uso terapéutico , Antagonistas de Dopamina/uso terapéutico , Receptores de Dopamina D2/metabolismo , Esquizofrenia/metabolismo , Antipsicóticos/química , Clozapina/uso terapéutico , Antagonistas de Dopamina/química , Diseño de Fármacos , Humanos , Receptores de Dopamina D2/efectos de los fármacos , Receptores de Dopamina D3 , Receptores de Dopamina D4 , Esquizofrenia/tratamiento farmacológico
10.
Artículo en Inglés | MEDLINE | ID: mdl-9533170

RESUMEN

1. Citicoline (cytidine (5') diphosphocholine) has been shown to reverse aging-induced memory deficits, scopolamine-induced amnesia and nucleus basalis magnocellularis lesion-induced learning impairment. 2. This study aimed to evaluate the effects of citicoline on learning and retrieval processes in a complex differential reinforcement of response duration schedule in normal dogs. 3. The effects of citicoline on a stabilized performance were also measured in order to be able to differentiate specific memory effects from non specific influences on the motor, neuro-vegetative and motivational systems. 4. The results demonstrate that citicoline can exert facilitatory effects on learning and memory but also on retrieval processes. The complete absence of effects on the stabilized performance and on the motor, neuro-vegetative and motivational systems constitutes arguments in favour of a selectivity of action on the memory processes.


Asunto(s)
Condicionamiento Operante/efectos de los fármacos , Citidina Difosfato Colina/farmacología , Memoria/efectos de los fármacos , Nootrópicos/farmacología , Estimulación Acústica , Análisis de Varianza , Animales , Perros , Conducta Exploratoria , Masculino , Refuerzo en Psicología , Recompensa , Factores de Tiempo
11.
J Cardiovasc Pharmacol ; 31(2): 271-6, 1998 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-9475269

RESUMEN

A multicenter, randomized, double-blind, crossover, placebo-controlled study was conducted in 90 isosorbide dinitrate responders showing stable angina to compare the efficacy of molsidomine retard, 8 mg b.i.d., with that of molsidomine, 4 mg t.i.d., for 6 weeks. Total work performance (workload x min) was significantly improved, compared with baseline and placebo until 8 and 12 h after molsidomine and molsidomine retard administration, respectively. ST-segment depression decreased significantly under the two treatments at 60 W as well as at maximal exercise. The rate-pressure product (heart rate x systolic blood pressure) decreased and increased significantly at submaximal and maximal exercise level, respectively. All these effects remained significant after 6-week treatment, with only the ST segment showing a nonsignificant tendency to improvement at maximal work. The frequency of anginal attacks and of sublingual nitroderivative-tablets consumption decreased significantly with molsidomine, 4 mg, and molsidomine retard, 8 mg. However, overall results showed that the latter form reduces myocardial ischemia more efficiently at submaximal exercise level, has a more prolonged effect on exercise tolerance, and maintains it at a somewhat higher level after 6-week treatment.


Asunto(s)
Angina de Pecho/tratamiento farmacológico , Molsidomina/administración & dosificación , Isquemia Miocárdica/tratamiento farmacológico , Vasodilatadores/administración & dosificación , Adulto , Anciano , Angina de Pecho/etiología , Muerte Súbita/etiología , Método Doble Ciego , Electrocardiografía , Prueba de Esfuerzo , Tolerancia al Ejercicio/efectos de los fármacos , Femenino , Cefalea/etiología , Hemodinámica/efectos de los fármacos , Humanos , Dinitrato de Isosorbide/uso terapéutico , Masculino , Persona de Mediana Edad , Molsidomina/efectos adversos , Calidad de Vida , Vasodilatadores/efectos adversos
12.
Behav Pharmacol ; 9(8): 731-7, 1998 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-9890262

RESUMEN

The interaction with monoamine oxidase A (MAO-A) and B has been shown to be sensitive to the absolute configuration of molecules. Therefore, the aim of this study was to compare the effects of the racemic pirlindole (a selective and reversible MAO-A inhibitor) and its two enantiomers using biochemical techniques (in vitro and ex vivo determination of rat brain MAO-A and MAO-B activity) and behavioural models (forced swimming test and reserpine-induced hypothermia and palpebral ptosis test). In vitro, the MAO-A IC50 of (+/-)-pirlindole, R-(-)-pirlindole and S-(+)-pirlindole were 0.24, 0.43 and 0.18 microM, respectively. Ex vivo, their ID50 were 24.4, 37.8 and 18.7 mg/kg i.p. The differences between the three compounds were not significant, with a ratio between the two enantiomers [R-(-)/S-(+)] of 2.2 in vitro and 2.0 ex vivo. MAO-B was only slightly inhibited. In the forced swimming test and the reserpine-induced hypothermia and ptosis model, the three compounds had an antidepressant profile. In the forced swimming test, the minimal effective dose ratio between the R-(-) and the S-(+) was again around 2.0. The behavioural observations were thus clearly in accordance with the biochemical data.


Asunto(s)
Antidepresivos/farmacología , Carbazoles/farmacología , Inhibidores de la Monoaminooxidasa/farmacología , Animales , Antidepresivos/química , Blefaroptosis/fisiopatología , Encéfalo/enzimología , Carbazoles/química , Femenino , Hipotermia/inducido químicamente , Hipotermia/fisiopatología , Ratones , Monoaminooxidasa/metabolismo , Inhibidores de la Monoaminooxidasa/química , Ratas , Ratas Wistar , Reserpina/toxicidad , Estereoisomerismo
13.
Biochem Biophys Res Commun ; 238(1): 252-5, 1997 Sep 08.
Artículo en Inglés | MEDLINE | ID: mdl-9299488

RESUMEN

The oxidation behaviour of JL 13, a promising antipsychotic, was investigated in comparison with clozapine and loxapine, by measuring their direct "radical scavenging" abilities and their efficacies in inhibiting the lipid peroxidation. In the lipid peroxidation system, the reactivity of these compounds with free radicals produced by gamma-irradiation of linoleic acid may be presented as follows: JL 13 = loxapine < clozapine. In two enzymatic systems (HRP/GSH and HRP/H2O2/ GSH) which generate the thiyl free radicals, clozapine produces a strong enhancement of the thiyl-radical EPR signal intensity while JL 13 and loxapine exhibit no or minimal effect on this signal. The redox potential values for the three derivatives confirm the spectro-photometric and EPR results. Following this study, we show that JL 13, although presenting a preclinical clozapine-like profile, appears less sensitive to oxidation than clozapine.


Asunto(s)
Antipsicóticos/metabolismo , Clozapina/análogos & derivados , Catálisis , Clozapina/metabolismo , Espectroscopía de Resonancia por Spin del Electrón , Loxapina/metabolismo , Oxidación-Reducción , Peroxidasa/metabolismo , Detección de Spin , Estereoisomerismo
14.
Acta Psychiatr Scand ; 96(2): 134-41, 1997 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-9272198

RESUMEN

The aim of this double-blind randomized study was to compare the efficacy and the tolerability of moclobemide (300-600 mg daily) and pirlindole (150-300 mg daily), two reversible inhibitors of MAO-A (RIMAs), in the treatment of depression. In total 116 patients were included in the trial, 111 patients (52 patients on pirlindole and 59 patients on moclobemide) were evaluable for efficacy and safety, and 77 patients completed the whole study (42 days of administration). Both treatments produced highly significant improvements in the Hamilton Depression Rating Scale (HDRS) score, the Hamilton Anxiety Rating Scale (HARS) score and the Montgomery-Asberg Rating Scale (MADRS) score from day 7 to day 42. The pattern of development of the three scores in the two groups did not differ significantly. After 42 days of treatment, an improvement of > or = 50% in the HDRS score was noted in 80% and 67% of patients in the pirlindole and moclobemide groups, respectively. A total of 30 (58%) patients on pirlindole and 33 (56%) patients on moclobemide experienced side-effects that were considered to be possibly or probably related to the medication. The differences between the two drugs were non-significant for all types of side-effect, with the exception of dry mouth and tachycardia, which were significantly more frequent with moclobemide.


Asunto(s)
Antidepresivos/uso terapéutico , Benzamidas/uso terapéutico , Carbazoles/uso terapéutico , Depresión/tratamiento farmacológico , Inhibidores de la Monoaminooxidasa/uso terapéutico , Adolescente , Adulto , Anciano , Análisis de Varianza , Distribución de Chi-Cuadrado , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Moclobemida , Estudios Prospectivos , Índice de Severidad de la Enfermedad , Factores de Tiempo , Resultado del Tratamiento
15.
Pharmacol Res ; 36(1): 23-33, 1997 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-9368911

RESUMEN

Pirlindole is a tetracyclic compound that has been characterized as a potential antidepressant drug. It has pharmacological characteristics in common with both tricyclic antidepressants and classical irreversible monoamine oxidase inhibitors. Its main mechanism of action consists of a selective and reversible inhibition of monoamine oxidase A. Secondarily, it exerts an inhibitory effect on noradrenaline and 5-hydroxytryptamine reuptakes. It has no effect on the dopaminergic and cholinergic systems. It has only a low potential for amplifying tyramine and noradrenaline pressor effect, which makes one expect that it will not be at the basis of a 'cheese effect'. Pirlindole has an absolute bioavailability of between 20 and 30% due to an extensive first-pass effect. Orally, the Tmax varies between 2.5 and 6 h in the rat and 0.8 and 2 h in the dog. Two phases of elimination (7.5 and 34-70 h) are measured in the rat and three phases in the dog (1.3, 10.8 and 185 h); it is extensively metabolized. The rat eliminates mainly unconjugated products while the dog eliminates mostly conjugated products. Acute and chronic toxicological studies have not revealed potentially dangerous effects of the drug at the usual doses. It does not present measurable mutagenic, clastogenic or carcinogenic properties. Thus, pirlindole shows pharmacological, pharmacokinetic and toxicological properties which make it suitable for the management of depression.


Asunto(s)
Antidepresivos/farmacología , Carbazoles/farmacología , Inhibidores de la Monoaminooxidasa/farmacología , Animales , Perros , Evaluación Preclínica de Medicamentos , Ratones , Ratas
16.
Pharmacol Res ; 36(4): 255-64, 1997 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-9425613

RESUMEN

The search for an improved clozapine-like compound has resulted in the selection of a new molecule: JL13 (5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5] benzoxazepine fumarate). Like clozapine, JL13 did not antagonize apomorphine-induced stereotypy and did not produce catalepsy but antagonized apomorphine-induced climbing in rodents (ID50 = 3.9 mg kg-1 s.c.). It was inactive against d-amphetamine-induced stereotypy but antagonized d-amphetamine-induced hyperactivity in the mouse (ID50 = 4.4 mg kg-1 i.p.). JL13, like clozapine, was able to antagonize (+/-)-DOI-induced head-twitches in the mouse (ID50 = 2.0 mg kg-1 i.p.). In the open-field test in the rat and forced swimming test in the mouse a high similarity was noted between the two drugs in the same range of doses. In a complex temporal regulation schedule in the dog, JL13 showed a high resemblance with clozapine without inducing sialorrhea, palpebral ptosis or any significant motor side effects. In rats trained to discriminate clozapine, JL13 (10 mg kg-1 i.p.) induced a high level of generalization (70%) to clozapine. In a drug discrimination procedure in the squirrel monkey, JL13 (3-10 mg kg-1 i.m.) produced a full substitution of clozapine. On the basis of these preclinical data, it is thus predicted that JL13 would be a promising atypical antipsychotic drug.


Asunto(s)
Antipsicóticos/farmacología , Conducta Animal/efectos de los fármacos , Clozapina/análogos & derivados , Clozapina/farmacología , Animales , Perros , Ratones , Ratas , Saimiri
17.
Acta Psychiatr Scand ; 94(6): 404-10, 1996 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-9020990

RESUMEN

The efficacy and safety of pirlindole (300 mg/day), a new reversible inhibitor of monoamine oxidase A, have been evaluated in a multicentre placebo-controlled double-blind randomized trial in 103 in-patients suffering from unipolar major depression (DSM-III-R 296.2, 296.3) over a 42-day period after a run-in placebo period of 6 days. Pirlindole produced a significantly greater decrease than placebo in the Hamilton depression score (from day 28), the Hamilton anxiety score (from day 28) and the Montgomery-Asberg depression score (on day 42). On day 42, the Hamilton depression score was < or = 7, > or = 8 and < or = 15, or > or = 16 in 21%, 45% and 34%, respectively, in the placebo group compared to 72%, 24% and 3.4%, respectively, in the pirlindole group (P < 0.001). The differences between the two groups in terms of tolerance and safety were not statistically significant.


Asunto(s)
Antidepresivos/uso terapéutico , Carbazoles/uso terapéutico , Trastorno Depresivo/tratamiento farmacológico , Inhibidores de la Monoaminooxidasa/uso terapéutico , Adulto , Antidepresivos/efectos adversos , Bélgica , Carbazoles/efectos adversos , Trastorno Depresivo/diagnóstico , Trastorno Depresivo/psicología , Método Doble Ciego , Monitoreo de Drogas , Femenino , Humanos , Masculino , Persona de Mediana Edad , Inhibidores de la Monoaminooxidasa/efectos adversos , Inventario de Personalidad , Resultado del Tratamiento
18.
Eur J Pharmacol ; 310(1): 9-12, 1996 Aug 22.
Artículo en Inglés | MEDLINE | ID: mdl-8880061

RESUMEN

JL3, 10-(4-methylpiperazin-1-yl)pyrido[4,3-b][1,4]benzothiazepine, has potent antidepressant-like activity in Porsolt's test in mice. Therefore, its influence on the electrical activity of central monoaminergic neurons was investigated in rats anaesthetized with chloral hydrate. JL3 induced a marked decrease of the firing rate of dorsal raphe serotonergic neurons (ID50 = 3.87 +/- 0.57 mg kg-1) and of locus coeruleus noradrenergic neurons (ID50 = 2.63 +/- 0.35 mg kg-1). The drug did not modify the electrical activity of A10 dopaminergic neurons. JL3 does not block amine uptake but it has affinity for 5-HT1A and 5-HT2 receptors. It is speculated that serotonergic mechanisms could play a role in the electrophysiological effects of JL3.


Asunto(s)
Antidepresivos/farmacología , Núcleos del Rafe/efectos de los fármacos , Tiazepinas/farmacología , Animales , Relación Dosis-Respuesta a Droga , Electrofisiología , Humanos , Locus Coeruleus/efectos de los fármacos , Ratas , Ratas Wistar
19.
Behav Pharmacol ; 6(8): 830-838, 1995 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-11224387

RESUMEN

Original bioisosteric analogues of clozapine were evaluated for potential disinhibitory and/or antidepressant effects using the open-field test in the rat and Porsolt's forced swimming test in the mouse. Attempts to relate the behavioural results to the binding affinities for dopamine (D1, D2), serotonin (5-HT(2)) and muscarinic (M) receptors were also undertaken. In the open-field test, two main profiles were observed. The first profile corresponded to disinhibitory molecules resembling diazepam and ritanserin. The second profile corresponded to antipsychotic compounds resembling either typical (haloperidol, clothiapine) or atypical (clozapine) neuroleptics. The results obtained in the forced swimming test confirmed the neuroleptic-like activity of the second group of compounds, while two compounds of the first group (JL 3 and JL 26) showed an antidepressant-like activity, JL 3 being as active as imipramine. While it was not possible to relate the first profile to any binding interaction, a relation could be established among the second group of compounds between the typical or atypical antipsychotic behavioural profile and the 5-HT(2)/D2 ratio.

20.
Eur J Pharmacol ; 273(3): R1-3, 1995 Feb 06.
Artículo en Inglés | MEDLINE | ID: mdl-7737323

RESUMEN

Clozapine has a more marked affinity for the recently cloned dopamine D4 receptor than for the dopamine D2 receptor. In the search for a selective ligand for the dopamine D4 receptor, useful as a pharmacological tool or as a potent atypical antipsychotic, a pyridobenzodiazepine derivative bioisoster of clozapine, JL 18, 8-methyl-6-(4-methyl-1-piperazinyl)-11H-pyrido [2,3-b][1,4]benzodiazepine, was found to be the most dopamine D4-selective ligand belonging to the diarylazepine class. Indeed, JL 18 binds to the dopamine D4 receptor with affinity up to 25 times superior to that for the dopamine D2 receptor and presents reduced affinities for other receptors.


Asunto(s)
Clozapina/análogos & derivados , Clozapina/farmacología , Antagonistas de Dopamina/farmacología , Receptores Dopaminérgicos/efectos de los fármacos , Apomorfina/análogos & derivados , Apomorfina/farmacología , Unión Competitiva/efectos de los fármacos , Células Cultivadas , Clozapina/química , Agonistas de Dopamina/farmacología , Antagonistas de los Receptores de Dopamina D2 , Humanos , Receptores de Dopamina D2/efectos de los fármacos , Receptores de Dopamina D4 , Espiperona/farmacología , Relación Estructura-Actividad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA